TGTX Stock Hits Fresh 52-Week High – Here’s Why Retail Is Bullish Despite Q1 Earnings Miss

• TG Therapeutics raised its full-year 2026 revenue outlook to about $925 million, from its earlier guidance of $875 - $900 million.
• Total revenue for Q1 rose to $204.9 million, driven primarily by U.S. Briumvi sales of $194.8 million.
• The company expects to report topline Phase 3 results from the Enhance trial of Briumvi around mid-2026.

Shares of TG Therapeutics Inc. (TGTX) surged more than 8% to their highest levels in over a year, as investors embraced upbeat guidance for Briumvi, its lead candidate for multiple sclerosis.

The company raised its full-year (FY) 2026 revenue outlook to about $925 million, from its earlier guidance of $875 - $900 million. It also increased its U.S. sales forecast for Briumvi to $885 - $900 million, up from the earlier $825 - $850 million range. For the second quarter (Q2), TG expects domestic Briumvi revenue of around $220 million.

“With multiple near-term clinical catalysts and ongoing efforts to expand the franchise, we believe Briumvi is well-positioned to become a leading therapy in MS and a durable, long-term growth driver for TG,” said Michael S. Weiss, Chairman and CEO.

TGTX’s Q1 Print Paint Mixed Picture

TG Therapeutics reported strong Q1 results, driven by growth in its lead product. Total revenue rose to $204.9 million, driven primarily by U.S. Briumvi sales of $194.8 million. This was higher than Wall Street’s $201.2 million estimate, according to Fiscal.ai data.

Revenue from licensing, milestones, and royalties totalled $3.6 million, up from $1.2 million last year.

The company posted net income of $19.8 million, or $0.12 per share. However, this came in sharply below consensus estimates of $0.27 per share.

The company expects to report topline Phase 3 results from the Enhance trial of IV Briumvi around mid-2026. It also plans to share early Phase 1 data for azer-cel in progressive multiple sclerosis in the second half of 2026.

TGTX: Retail Turns Extremely Bullish

Retail sentiment for TGTX on Stocktwits turned to ‘extremely bullish’ from ‘neutral’ a day earlier, amid ‘high’ message volumes.

One user said that the noise around missing earnings estimates should be ignored.

Another user expects growth to accelerate throughout 2026.

The stock has jumped nearly 28% year-to-date.

Read also: TNXP Stock Climbs 7%: Retail Bets On $30M Revenue Upside From Tonmya Deal

For updates and corrections, email newsroom[at]stocktwits[dot]com.